Rogers (ROG)
(Delayed Data from NYSE)
$104.47 USD
+3.31 (3.27%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $104.50 +0.03 (0.03%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth D Momentum C VGM
Price, Consensus and EPS Surprise
ROG 104.47 +3.31(3.27%)
Will ROG be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ROG based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ROG
Is ALPS International Sector Dividend Dogs ETF (IDOG) a Strong ETF Right Now?
Is Vanguard International Dividend Appreciation ETF (VIGI) a Strong ETF Right Now?
ROG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Rogers Corp. (ROG) Q2 Earnings Beat Estimates
What to Expect From These 3 Electronics Stocks in Q2 Earnings?
TE Connectivity (TEL) Q3 Earnings Beat Estimates
Other News for ROG
FDA Approves Ocrevus Zunovo? as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis
FDA Approves Genentech?s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
Roche advances AI-driven cancer diagnostics by expanding its digital pathology open environment
Ram Mayampurath to Join MKS Instruments as Chief Financial Officer
MKS Instruments announces new CFO